Results 161 to 170 of about 98,172 (269)

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia. [PDF]

Cancer Res
Luo Z, Lin C, Yu C, Yuan C, Wu W, Xu X, Sun R, Jia Y, Wang Y, Shen J, Wang D, Wang S, Jiang H, Jiang B, Yang X, Xie C.   +15 more
europepmc   +1 more source

Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin. [PDF]

Cell Cycle, 2023
Yin SS, Chen C, Liu Z, Liu SL, Guo JH, Zhang C, Zhang QW, Gao FH.   +7 more
europepmc   +1 more source

Co-Occurrence of Jak2-Positive Myelofibrosis and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. [PDF]

Mediterr J Hematol Infect Dis
Paciaroni K, Campagna S, Villiva N, Maffini E, Celesti F, Tordi A, Lombardi M, Dragonetti G, di Toritto TC.   +8 more
europepmc   +1 more source

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

Leukemia, 2014
Mathias Schmidt, J. Rinke, V. Schäfer, S. Schnittger, A. Kohlmann, E. Obstfelder, Christa Kunert, J. Ziermann, N. Winkelmann, E. Eigendorff, T. Haferlach, C. Haferlach, A. Hochhaus, T. Ernst   +13 more
semanticscholar   +1 more source

Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa. [PDF]

EJHaem
Ayalew ZS, Azibte GT, Tadesse F, Legesse BA, Kiflu ZG, Weldeamanuel MT, Tsige KA, Molla BA, Ejigu AM.   +8 more
europepmc   +1 more source

Bcr/Abl associated leukemogenesis in bcr null mutant mice

, 1998
Jan Willem Voncken, Vesa Kaartinen, John Groffen, Nora Heisterkamp   +3 more
openalex   +1 more source

Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells [PDF]

, 2000
Alec W. Gross, Ruibao Ren
openalex   +1 more source

A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia

Science Translational Medicine, 2014
Leyuan Ma, Y. Shan, R. Bai, Liting Xue, C. Eide, Jianhong Ou, L. Zhu, L. Hutchinson, J. Černý, H. Khoury, Z. Sheng, B. Druker, Shaoguang Li, Michael R. Green   +13 more
semanticscholar   +1 more source

The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase [PDF]

, 2000
Ryan P. Million, Richard A. Van Etten
openalex   +1 more source

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

Cancer, 2014
S. Soverini, C. De Benedittis, C. Papayannidis, S. Paolini, C. Venturi, I. Iacobucci, M. Luppi, P. Bresciani, M. Salvucci, D. Russo, S. Sica, E. Orlandi, T. Intermesoli, A. Gozzini, M. Bonifacio, G. Rigolin, F. Pane, M. Baccarani, M. Cavo, G. Martinelli   +19 more
semanticscholar   +1 more source